Literature DB >> 15994776

A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.

Dan H Barouch1, Zhi-yong Yang, Wing-pui Kong, Birgit Korioth-Schmitz, Shawn M Sumida, Diana M Truitt, Michael G Kishko, Janelle C Arthur, Ayako Miura, John R Mascola, Norman L Letvin, Gary J Nabel.   

Abstract

Plasmid DNA vaccines elicit potent and protective immune responses in numerous small-animal models of infectious diseases. However, their immunogenicity in primates appears less potent. Here we investigate a novel approach that optimizes regulatory elements in the plasmid backbone to improve the immunogenicity of DNA vaccines. Among various regions analyzed, we found that the addition of a regulatory sequence from the R region of the long terminal repeat from human T-cell leukemia virus type 1 (HTLV-1) to the cytomegalovirus (CMV) enhancer/promoter increased transgene expression 5- to 10-fold and improved cellular immune responses to human immunodeficiency virus type 1 (HIV-1) antigens. In cynomolgus monkeys, DNA vaccines containing the CMV enhancer/promoter with the HTLV-1 R region (CMV/R) induced markedly higher cellular immune responses to HIV-1 Env from clades A, B, and C and to HIV-1 Gag-Pol-Nef compared with the parental DNA vaccines. These data demonstrate that optimization of specific regulatory elements can substantially improve the immunogenicity of DNA vaccines encoding multiple antigens in small animals and in nonhuman primates. This strategy could therefore be explored as a potential method to enhance DNA vaccine immunogenicity in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994776      PMCID: PMC1168733          DOI: 10.1128/JVI.79.14.8828-8834.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.

Authors:  L Musey; J Hughes; T Schacker; T Shea; L Corey; M J McElrath
Journal:  N Engl J Med       Date:  1997-10-30       Impact factor: 91.245

2.  Immunization for Ebola virus infection.

Authors:  L Xu; A Sanchez; Z Yang; S R Zaki; E G Nabel; S T Nichol; G J Nabel
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

3.  Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens.

Authors:  J J Kim; N N Trivedi; L K Nottingham; L Morrison; A Tsai; Y Hu; S Mahalingam; K Dang; L Ahn; N K Doyle; D M Wilson; M A Chattergoon; A A Chalian; J D Boyer; M G Agadjanyan; D B Weiner
Journal:  Eur J Immunol       Date:  1998-03       Impact factor: 5.532

4.  Development of improved vectors for DNA-based immunization and other gene therapy applications.

Authors:  J A Norman; P Hobart; M Manthorpe; P Felgner; C Wheeler
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

Review 5.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

6.  The RU5 ('R') region from human leukaemia viruses (HTLV-1) contains an internal ribosome entry site (IRES)-like sequence.

Authors:  J Attal; M C Théron; F Taboit; M Cajero-Juarez; G Kann; P Bolifraud; L M Houdebine
Journal:  FEBS Lett       Date:  1996-09-02       Impact factor: 4.124

7.  Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines.

Authors:  Z Xiang; H C Ertl
Journal:  Immunity       Date:  1995-02       Impact factor: 31.745

8.  Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.

Authors:  S Calarota; G Bratt; S Nordlund; J Hinkula; A C Leandersson; E Sandström; B Wahren
Journal:  Lancet       Date:  1998-05-02       Impact factor: 79.321

9.  First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.

Authors:  R R MacGregor; J D Boyer; K E Ugen; K E Lacy; S J Gluckman; M L Bagarazzi; M A Chattergoon; Y Baine; T J Higgins; R B Ciccarelli; L R Coney; R S Ginsberg; D B Weiner
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

10.  Sequence requirements of ATF2 and CREB binding to the human T-cell leukemia virus type 1 LTR R region.

Authors:  X Xu; S H Kang; O Heidenreich; D A Brown; M I Nerenberg
Journal:  Virology       Date:  1996-04-15       Impact factor: 3.616

View more
  101 in total

1.  Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.

Authors:  Anita Changela; Xueling Wu; Yongping Yang; Baoshan Zhang; Jiang Zhu; Glenn A Nardone; Sijy O'Dell; Marie Pancera; Miroslaw K Gorny; Sanjay Phogat; James E Robinson; Leonidas Stamatatos; Susan Zolla-Pazner; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

2.  Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.

Authors:  Wing-pui Kong; Ling Xu; Konrad Stadler; Jeffrey B Ulmer; Sergio Abrignani; Rino Rappuoli; Gary J Nabel
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Authors:  Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

4.  Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation.

Authors:  Jinyan Liu; Rune Kjeken; Iacob Mathiesen; Dan H Barouch
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

Review 5.  Post-step modifications for research on HIV vaccines.

Authors:  Lawrence Corey; M Juliana McElrath; James G Kublin
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

6.  HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.

Authors:  Lifei Yang; Yufeng Song; Xiaomin Li; Xiaoxing Huang; Jingjing Liu; Heng Ding; Ping Zhu; Paul Zhou
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

7.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

8.  Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.

Authors:  Gilad Ofek; Krisha McKee; Yongping Yang; Zhi-Yong Yang; Jeff Skinner; F Javier Guenaga; Richard Wyatt; Michael B Zwick; Gary J Nabel; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

9.  A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.

Authors:  Elizabeth S Gabitzsch; Younong Xu; Lois H Yoshida; Joseph Balint; Richard B Gayle; Andrea Amalfitano; Frank R Jones
Journal:  Immunol Lett       Date:  2008-12-13       Impact factor: 3.685

Review 10.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.